Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
31 In addition, there is no evidence to support the use of LOLA in patients with acute liver failure
As of 2026, it was removed from the FDA's Category 2 restriction list and is under active review by the Pharmacy Compounding Advisory Committee, with a scheduled meeting on July 23, 2026, to evaluate its inclusion on the 503A Bulk Drug Substances List
The present study has identified enhanced PS exposure at the surface of erythrocytes as a potential risk factor for anemia and a contributor to its development in patients with CRF undergoing PD
Nauck MA et al (2011): Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans
US$ 23.54
US$ 26.26
US$ 21.81
US$ 28.42
US$ 27.58
US$ 26.74
